Exozymes Inc. · NASDAQ:EXOZ
Exozymes — Investor Presentation (October 2025)
31 slides from Exozymes's investor presentation, Oct 3, 2025
Slide 1: Leading the biomanufacturing revolution
exo/7ymes Leading the biomanufacturing revolution Breakthrough technology. Unmatched scaling capability. Accelerating time-to-market.
Slide 2: eXoZymes' Safe Harbor
eXoZymes’ Safe Harbor This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can general
Slide 3: Enzymes = AI = eXoZymes
enzymes = Al = exozymes
Slide 4: The problem
exXezymes The problem We all hoped for synthetic biology to change the world...
Slide 5: Plant-derived, petroleum-based, cell-based chemicals
Resources > Plant-derived Petroleum-based Cell-based chemicals chemicals synthetic biology
Slide 6: Plant-derived, petroleum-based, cell-based synthetic biology
Plant-derived Petroleum-based Cell-hased chemicals chemicals synthetic biology
Slide 7: We all hoped for SynBio to change the world...
We all hoped for SynBio to change the world... Cell-free finally unlocks the potential 8 Q Traditional SynBio Cell-Free Technology Market Potential Limited by cellular constraints No cellular limitations Unlimited scalability Complex optimization required Direct enzyme utilization Broader applicatio
Slide 8: Old SynBio paradigm: how cells make chemicals
Old SynBio paradigm: How cells make chemicals Sugar/Feedstock 5 O ary aee) G0" 030 O° exXxo7Z7ymes \
Slide 9: Top reasons why SynBio / cells / fermentation is not ideal
eXozymes \ Top reasons why SynBio / cells / fermentation is not ideal Cells are, by evolution, designed to only do things that help the cell survive, grow, and replicate. They do not want to produce chemicals they do not need. 2 | The cells often get sick or die from the toxic chemicals or the inter
Slide 10: Our Solution
exXezymes Our Solution The ingenuity of biology + the power of Al-driven enzyme engineering + the scalability of chemical production
Slide 11: How are exozymes different to synthetic biology?
How are exozymes different to synthetic biology?
Slide 12: Old SynBio paradigm: eXoZymes
Old SynBio paradigm: eXezymes How cells makes chemicals Why not just liberate the Sugar sedstock Enzymatic Pathway from the cell? 02% 0G 292° 80 5e e OM~O Qos , © e-* @ e » e Former belief system: Enzyme Pathways do not function outside of cells...
Slide 13: Cell-based enzymes vs exozyme biosolutions
eXezymes Cell-based enzymes - vs - exozyme biosolutions cell-based synbio = exozyme biosolutions = exozymes (Al-optimized enzymes) + production pathways helper modules Sugar/Feedstock Pays) Biomass/Sugar/ Cell-free Exozyme Pathway Chemistry 98%.0° Feedstock & Support Modules Product MOP OF OF + Engi
Slide 14: From prototype idea to commercial feasibility in weeks or months
From prototype idea to commercial feasibility in eels or months Idea Lab Scale Commercial Scale Picking the most promising molecule Process optimization Full market deployment 0% asset maturity 50% asset maturity in months 100% asset maturity Proof-of-Concept Pilot Scale Concept validation Commercia
Slide 15: Proven scale-up: kilo scale already mastered
Proven scale-up: Kilo scale already mastered POC & Lab Scale Milligrams to grams Pilot Scale Kilos ne Production Scale Ton scale
Slide 16: De-risking: SynBio versus cell-free
De-risking: SynBio versus cell-free High risk 25% 50% 75% Current SynBio Proof-of-Concept Lab scale Pilot scale Cell-free biosolutions Low risk eXezymes H ' i ' i ' t i i i ' Commercial scale q H i ! i i H | | i i I i Project phases to.completion
Slide 17: De-risking: SynBio versus cell-free
De-risking: SynBio versus cell-free Xezines High risk Low risk 25% Proof-of-Concept Cell-free biosolutions 50% 75% 100% Current SynBio Competitive advantage Lab scale Pilot scale Commercial scale Project phases to.completion 7
Slide 18: What's the business model?
What's the business model?
Slide 19: Business model overview
Business model overview Acapital-light 9 20 orm-o/-ple"orms approach Core Technology Platform Enzyme engineering and cell-free production tech form the foundation Multiple Revenue Streams Grants, contracts, equity stakes, licensing fees, royalties, and enzyme sales fr & & Target Identification Selec
Slide 20: Focusing on high-value natural products
Focusing on high-value natural products with pharmaceutical potential and extraordinary business cases Natural Health Products Pharmaceutical Analogs * $500-$5,000/kg compounds + $5,000-$500,000+/kg compounds + Rapidly growing market * Higher barriers to entry
Slide 21: Pipeline of high-value business opportunities
Pipeline of high-value business opportunities eXoZymes is strategically building a portfolio of high-value business opportunities, creating ownership stakes in companies, JVs and JVs and partnerships that leverage our breakthrough technology for competitive advantages in billion-dollar markets. ————
Slide 22: Total Addressable Markets (TAM)
Total Addressable Markets (TAM) Asset NcT (OTC) NCT (pharma) Cannabinoid-like molecules Santalene Application Health Supplements Metabolic health + obesity + NAFLD + IBS Medical & consumer Flavors & fragrances TAM $998 $65B $5.38 $163M + opens new markets Stage Finishing lab scale Preclinical Scale-
Slide 23: Selection of valuable molecules
Selection of valuable molecules Traditional chemistry Complex synthesis steps Highly polluting High energy requirements $$$ Cost Natural extraction Limited natural sources Environmental impact + Supply chain vulnerabilities * $$$ Cost 23
Slide 24: AI-driven enzyme engineering meets cell-free biomanufacturing
Al-driven enzyme engineering meets cell-free biomanufacturing Al design Rapid testing Large Language Models used + Thousands of variants tested to upgrade enzymes to become weekly become exozymes + Millions of data points * Continuous loop of generating generated per experiment - fed data to increas
Slide 25: Asymmetric upside
Asymmetric upside Strategic Partnerships a Product co-development Non-Dilutive Grants Shared commercialization journey $17M+ secured to date Aa Partly funds core R&D without dilution Proprietary Assets 2 12+ patent families Exclusive molecule rights Leveraging external funding, partnerships and IP t
Slide 26: About us
About us
Slide 27: Damien Paul
Damien Paul Perriman Opgenorth, cco PhD VP of Development Tyler Korman, PhD VP of Research Michael Heltzen CEO Fouad Nawaz VP of Finance Zachary Lasse H. Karl, PhD Gorlitz VP of Business VP of Development Comms 2
Slide 28: eXoZymes Background
eXoZymes Background » Location: Los Angeles, CA. » Size: 30 FTEs and a very large support system. » 2019: UCLA spin-out - Big Idea status = MDB Capital backed. » 2020: POC projects and technology platform development. » 2023: AI/ML and state-of-the-art enzyme engineering capabilities. » 2024: Commer
Slide 29: The market leader of cell-free biomanufacturing
The market leader of cell-free biomanufacturing yohootfinanee a nw 5 ry aN s : ot vy ee renenvie;eniaqumntripnaionatincembarenivnr ys BioClick - an enzyme engineering game- 2 changer, launched by eXoZymes and supported by a $300K NIH grant ’s in a Name: Out with Im
Slide 30: The future of biomanufacturing is cell-free.
The future of biomanufacturing is cell-free. And the future is bright!
Slide 31: @exozymes.com
@exozymes.com